Closing on Nov. 17: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors

Genedrive plc

Genedrive plc

Sector: Medical Laboratories Region: United Kingdom

: | London Stock Exchange: GDR

Genedrive plc is an established Biotechnology Company with headquarters in Manchester UK, and facilities in the US. Established initially as Epistem Ltd in 2000 by Prof. Chris Potten and Dr. Cath Booth, Epistem's scientific foundation was based on several decades of ground-breaking stem cell research by Prof. Potten. Based at the Paterson Institute for Cancer Research at the Christie Hospital and the University of Manchester, UK, Prof. Potten identified and characterised the location and behaviour of stem cells in the intestine, skin, hair follicle and breast. To support this revolutionary research, the team developed powerful models and assays to understand the controls of epithelial cell turnover and methods to quantify tissue damage, regeneration and metaplasia. As a result of increasing demand from pharmaceutical and biotechnology companies for access to these models, Prof. Potten and Dr. Booth formed Epistem.

In 2001, Epistem moved into the current purpose-built facilities at the heart of the vibrant scientific, medical and academic community of Manchester. In 2014, a second laboratory facility was opened in Baltimore, MD, to provide local support to Epistem's customers in the USA. The addition of sales offices in Massachusetts and Maryland continue to support a growing demand for services and the expansion of Epistem within the USA.

Epistem floated on the London AIM market in April 2007 trading as Epistem Holdings Plc (LSE: EHP). A subsequent change to genedrive plc occurred in 2016. genedrive plc operates a combined business model integrating the strengths of three complementary divisions.


David Budd, Chief Executive Officer
David was appointed a Director and Chief Executive on March 1, 2016. He has over 20 years of international commercial and operational experience in the diagnostics and medical devices field. He previously served as General Manager of Leica Biosystems Amsterdam and Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, product development, and commercial launches for diagnostic tests. Prior to Leica, David’s roles included Point-of-Care, molecular, and central laboratory marketing and commercialisation responsibilities at Siemens Healthcare Diagnostics, Bayer Diagnostics, and Visible Genetics.
Ian Gilham, Ph.D., Non-Executive Chairman
Ian was appointed a Director on 24 November 2014 and as Non-Executive Chairman on 11 May 2015. He is currently Non-Executive Chairman of three life sciences companies including AIM quoted Horizon Discovery Group Plc, which provides gene-editing tools to support translational genomics and the development of personalised medicine, Multiplicom NV focussed on the development and commercialisation of next generation DNA sequencing products and Biosurfit SA, focussed on development and commercialisation of point-of-care diagnostic products. Dr Gilham was formerly Chief Executive Officer of Axis-Shield Plc.
John Rylands, Financial Director
John originally joined Epistem, now genedrive plc, as an investor and Non-Executive Director, and became Finance Director in 2005. John provided corporate finance advice to private companies before joining Epistem. Until 1999 he was an investor in and consultant to the SDS group of companies. John holds a degree in Economics and Accountancy from the Manchester University and is a member of ICAEW.
Catherine Booth, Ph.D., Managing Director, Contract Research Services
Catherine is a co-founder of Epistem and prior to starting Epistem she worked for 10 years with Prof. Chris Potten at the Paterson Institute.  Whilst at the Paterson Institute she developed many preclinical assays.  This knowledge is at the core of the Epistem Contract Research Service.  Catherine received her Ph.D. from the Emmanuel College, University of Cambridge.
Allan Brown, Ph.D., Chief Operating Officer, Diagnostics Division
Allan has spent his career in the Life Sciences/diagnostics industry. During a seventeen year period with Tepnel Life Sciences plc, latterly as Divisional Managing Director, Allan's technical management roles covered product development through to commercial product launch; his commercial management roles covered sales and business development and M&A. Allan left Tepnel in 2010 following its recommended US$132m cash offer by Gen-Probe Inc. in 2009. At the time of the offer by Gen-Probe Inc. Tepnel employed over 200 employees and had operations in the UK, US, Belgium and France. After leaving Tepnel/Gen-Probe, Allan joined the leading Sample & Assay Technologies company, QIAGEN N.V., in Manchester and managed the final development and launch of the company's first US FDA approved products, helping secure the site as QIAGEN's Global Centre of Excellence for molecular diagnostic product development. Allan was appointed to the Board on 1st February, 2014.
Robert Nolan, Ph.D., Non-executive Director
Robert has been a Non-executive Director of the Company since 2004.  He brings with him a wealth of expertise in partnering and licensing negotiations both with small biotechnology and large pharmaceutical companies. Prior to his retirement he was Director, Global Licensing at AstraZeneca.  He is also a non-executive Director of Phico Therapeutics Ltd.
Roger Lloyd, Ph.D., Non-executive Director
Trained as a biochemist, Roger has almost 35 years' experience in the healthcare and biotechnology sector, particularly in the areas of strategic planning and business development.  International business management with ICI Plc and AstraZeneca Plc included living and working in the US and Germany, and having territorial responsibilities for Europe, Japan, Korea, Mexico and the Middle East.  As Executive Director of Global Licensing at AstraZeneca, he personally completed 24 transactions, including strategic alliances with Abgenix and CAT, and acquisitions of KuDOS Pharmaceuticals and CAT.  He operates as a Board Adviser in the biotech sector.

News & Analysis